ICICI Lombard's Q4: GWP Strong, Profit Misses; Analysts Reiterate Buy

ICICI Lombard released its Q4 FY26 results, showing strong Gross Written Premium (GWP) growth but missing profit expectations. The company's Net Earned Premium (NEP) and Profit After Tax (PAT) were impacted by lower investment income and an impairment charge on its equity portfolio.

The insurer's GWP increased by a robust 17% year-on-year to INR 80.7 billion, meeting market forecasts. However, NEP grew 11% to INR 57.9 billion, falling 6% short of analyst estimates. PAT saw a modest 7% year-on-year rise to INR 5.5 billion, but this was a substantial 23% below projections. The shortfall was primarily attributed to lower-than-expected investment income and a ₹0.5 billion impairment on the company's equity holdings.

Despite profit pressures, operational metrics improved. The claims ratio held steady at 70.8%, and the expense ratio remained flat at 12.1%. This led to a combined ratio of 101.2% for the quarter, better than the brokerage estimate of 102.5%. For the full fiscal year 2026, the combined ratio was 103.4%. ICICI Lombard proposed a final dividend of ₹7 per share for FY26, subject to shareholder approval.

As of April 15, 2026, the stock closed at ₹1,858.00, up 4.25% for the day. The company's market capitalization was around ₹93,000-94,000 crore, with a trailing twelve-month P/E ratio in the range of 30-33x.

For FY26, ICICI Lombard's combined ratio was 103.4%, an improvement from 102.8% in FY25 but still above the 100% breakeven point. Competitors like Star Health reported a more favorable combined ratio of 98.9% in Q3 FY26, showcasing stronger underwriting profitability. The broader Indian general insurance sector is expected to grow significantly, with GWP projected to increase 9% in FY26 and a compound annual growth rate of 6.9% from 2026-2030, driven by demand for health and motor insurance.

Analyst sentiment largely remains positive, with a consensus 'Buy' rating and an average 12-month price target of approximately ₹2,118.73. Motilal Oswal reiterated its 'Buy' rating with a target of ₹2,230, citing operational efficiency and the company’s retail health segment momentum. However, some analysts, like Morgan Stanley with an 'Equal-Weight' rating and ₹1,920 target, suggest a more cautious view.

Key concerns include the recurring impact of equity portfolio impairments on profits. While the combined ratio is improving, it remains above 100%, indicating reliance on investment gains for overall profitability.

Motilal Oswal's target price of ₹2,230 is based on FY28 estimated earnings per share, a longer-term projection that carries execution risks. The company's Price-to-Book (P/B) ratio of about 5.6 is higher than some peers' historical valuations, potentially limiting upside if growth slows. The stock's performance over the past year has been modest compared to broader market indices. One analyst recently upgraded the stock from 'Sell' to 'Hold' based on technical factors, rather than fundamental performance shifts.

Motilal Oswal forecasts the combined ratio to fall to 101.8% by FY28, supported by stable claims and operational efficiency. HDFC Securities and Nuvama Institutional Equities also have 'Buy' ratings with targets of ₹2,210 and ₹2,350, respectively. The average analyst target suggests over 18% potential upside from current levels. The company's focus on retail health and disciplined growth is expected to support future profitability, in line with the expanding Indian insurance market.